Streetbeat News

Products Services

AAPL

Valve has stopped supporting Counter-Strike 2 on Apple Inc's Mac due to a low player base and technical limitations. The company is now focusing exclusively on 64-bit Windows and Linux support. Valve is providing a 'legacy' version of Counter-Strike: Global Offensive for Mac users who can't run Counter-Strike 2 on their current hardware. Support for this legacy version ends on Jan. 1, 2024.

Portfolio Pulse from Franca Quarneti

October 11, 2023 | 4:51 pm

DIS

Walt Disney Company (NYSE:DIS) is reportedly increasing ticket prices at its Disneyland resort by up to 9% and annual pass prices at Walt Disney World by up to 10%. The company has refrained from increasing daily entry fees in Florida due to subdued attendance in the recent quarter. The price of other amenities and offerings, such as the Enchant annual pass and the Genie+ service, are also rising. Last month, Disney announced plans to invest $60 billion in its parks division over the next decade.

Portfolio Pulse from Shivani Kumaresan

October 11, 2023 | 4:47 pm

DAL

EIS

Delta Air Lines has extended its travel waiver for all customers with travel booked to/from Tel Aviv, offering refund options and cancellations. Customers can rebook their travel on available flights through September 6, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:41 pm

V

Visa has introduced Entriva, a new travel document experience aimed at simplifying global travel. The new product is expected to make travel more stress-free for users.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:24 pm

LLY

Eli Lilly's shares are trading higher due to positive developments in Novo Nordisk's semaglutide FLOW kidney trial. Eli Lilly produces a similar GLP-1 drug to Novo's Ozempic, known as Mounjaro.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:24 pm

LLY

NVO

Eli Lilly's shares are trading higher due to positive developments in Novo Nordisk's semaglutide FLOW kidney trial. Eli Lilly produces a similar GLP-1 drug to Novo's Ozempic, known as Mounjaro.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:23 pm

LLY

NVO

Eli Lilly's stock is trading higher, possibly due to Novo Nordisk halting its kidney outcomes trial FLOW due to early signs of success. Eli Lilly produces a similar drug to Novo's Ozempic, called Mounjaro. Morgan Stanley has maintained an Overweight rating for Eli Lilly and raised the price target from $640 to $673, citing improved estimates for Mounjaro's sales from 2024 to 2026.

Portfolio Pulse from Adam Eckert

October 11, 2023 | 4:16 pm

PMVP

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) announced it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data will be discussed by the company's Chief Medical Officer and other experts during the conference. PMV will also host a KOL webinar to review the data and provide a regulatory update.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:05 pm

SNE

Sony has announced a new, smaller model of its PlayStation 5 (PS5) console, set to release on November 10. The new model is 30% smaller and 18% lighter than the current model, with a 20% increase in storage capacity. The price of the new model will be higher due to increased material costs. Sony aims to sell 25 million PS5 consoles worldwide by March 2024. The company hopes the new model will boost sales, following a similar strategy used with the PS4.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:00 pm

PHIO

Phio Pharmaceuticals announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This announcement led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:00 pm